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Gastric cancer in China
Gastric cancer (GC) is a heterogeneous disease with large 
variations across geographical regions. Although the global 
incidence of GC is declining, it remains highly prevalent 
in Asia as compared to the West (1). China is one of the 
countries with the highest incidence of GC, and accounts 
for over 40% of all new GC cases in the world (2). GC is 
the third leading cause of cancer mortality in China (3).
Regional differences in patient outcomes and response 
to treatment in GC have also been observed. In a 
study comparing GC patients in the Memorial Sloan-
Kettering Cancer Center in New York City (n=711) with 
those from Korea (n=1,646), the disease-specific survival for 
Korean patients was significantly better after adjusting for all 
known confounding factors (hazard ratio of 1.3, P=0.05) (4). 
Similarly in the AVAGAST trial, a phase III study of 
first-line chemotherapy plus bevacizumab in advanced 
GC, the intrinsic prognosis of Asian patients was shown 
to be better than Americans; however, the addition of 
bevacizumab to chemotherapy improved the survival of 
American patients only (5). Regarding safety in systemic 
treatment for GC, a meta-analysis of 8 Asian and 17 
Western or international trials showed that geographical 
region (Asian vs. non-Asian) was an independent predictor, 
with Asian trials associated with lower incidence of grade 
3-4 neutropenia and diarrhea (6).
There are postulations that these geographical 
differences in epidemiology and patient outcomes may be 
explained by distinct tumor biology and etiology. A number 
of gene polymorphisms, including those of the DNA repair 
gene XRCC1, were found to be associated with GC risk 
in the Chinese population (7-10). Other studies suggested 
differential prevalence of oncogene mutations in China 
and other parts of the world. For example, while RAS 
mutations were reportedly rare in Western Europe and 
Japan, their prevalence in China was up to 30% (11-13). 
The prevalence of PIK3CA mutations was however much 
lower in a Chinese cohort than generally reported (14). 
Furthermore, differences in GC genetic instability patterns 
across geographical origins may also exist, as suggested 
by a study comparing African patients and those from the 
United Kingdom (15).
The high prevalence of Helicobacter pylori (H. pylori) 
infection and the local circulating genotypes being highly 
carcinogenic (16) are of particular etiological significance 
in China and contribute to the geographical difference. A 
randomized placebo-controlled primary prevention trial 
in China demonstrated a reduction in GC development 
with eradication of H. pylori in the subgroup of healthy 
carriers without precancerous lesions at baseline, although 
the overall incidence of GC in the eradication and placebo 
groups was similar at 7.5 years (17). The association 
between the decline in H. pylori prevalence in China and the 
decline in gastric cancer incidence was also reported by an 
epidemiological study (18).
Other environmental factors such as lifestyle, diet and 
socioeconomic status play a role in gastric carcinogenesis. 
China is the largest tobacco production and consumption 
country in the world, consisting of more than 300 million 
current smokers (19), and GC risk among the Chinese 
population is significantly associated with tobacco smoking 
as shown in a meta-analysis (20). The Chinese taste for 
preserved, salty, fried foods and hot soup, and the low intake 
of certain vitamins and micronutrients are associated with 
risk of GC (21). Concordantly, dietary supplementation 
of nutrients such as vitamin C, selenium and carotene 
was shown in prevent GC in Chinese (22,23) but not in 
Caucasian populations (24,25). 
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On the other hand, part of the perceived geographical 
difference in GC may simply be related to regional 
variation in the prevalence of different GC subtypes and 
their different prognosis. While proximal tumors are more 
common in industrialized nations and tumors of the intestinal 
histology in Asia, there is no evidence that patient outcomes 
for particular subtypes differ between regions (26). Different 
patient outcomes may also be explained by variation in 
population screening programs; at diagnosis tumors are 
generally of earlier stage in Korea that in the United States (4).
Taken together, GC in Chinese patients is different 
from that occurring in the West, and is a significant health 
burden. Moreover, there is currently no internationally 
accepted standard treatment regimen and clinical practice 
varies widely across countries. An updated guideline 
specific for the Chinese population is therefore warranted. 
The Gastric Cancer Diagnosis and Treatment Expert Panel 
of the Chinese Ministry of Health: Chinese guidelines for 
diagnosis and treatment of gastric cancer (2011 edition) (“the 
Chinese Guidelines”) are timely published in the latest issue 
of Translational Gastrointestinal Cancer (27). While the 
Chinese Guidelines provide a comprehensive account in the 
scientific area, a few points will be highlighted here.
Surgical and adjuvant treatment
Extended (D2) lymph node dissection is recommended in 
the Chinese Guidelines as the standard surgery for operable 
GC except for early disease limited to the mucosa or 
submucosa with no lymph node involvement. Although D2 
resection is regarded as the standard of care in Asia, its role 
has been more controversial in the West, where previous 
trials failed to show any survival advantage with D2 over 
D1 dissection (28-31). However, more recent long-term 
follow-up results of a Dutch trial showed D2 surgery was 
associated with a lower rate of disease-related death than 
D1 surgery (32). Given that other reports from Western 
countries confirmed better outcomes with D2 surgery when 
performed in experienced centers (33-35), latest Western 
guidelines now recommend the inclusion of D2 dissection 
as the standard surgery for GC (36).
Adjuvant treatments currently used in the West, 
including peri-operative chemotherapy (37) or post-
operative chemoirradiation (38),  were established 
before D2 surgery became standard. The less aggressive 
surgery may explain the benefits of the more intensive 
adjuvant treatments. On the other hand, post-operative 
chemotherapy alone is effective as adjuvant treatment after 
D2 surgery in Asian trials (39,40). Moreover, a Korean study 
comparing chemotherapy with or without radiotherapy 
after D2 surgery did not show improved outcomes with 
the addition of radiotherapy (41). These findings support 
the choice of adjuvant therapy based on the level of surgery 
(D2 versus D0/1) performed, as detailed in the Chinese 
Guidelines. 
Systemic therapy for advanced disease 
Systemic options to treat advanced GC including 
chemotherapy and targeted therapy are similar in the 
East and West. In particular, the addition of trastuzumab 
to chemotherapy significantly improved response, 
progression free survival and overall survival in advanced 
GC patients with human epidermal growth factor (HER)-
2-positive disease, defined by immunohistochemical 
(IHC) staining 3+ or fluorescence in-situ hybridization 
(FISH)-positive, in the phase III ToGA trial (42). The 
greatest benefit was seen in patients with higher levels 
of HER2 expression with either IHC3+ or IHC2+ plus 
FISH+. HER2-positive rate is higher in gastroesophageal 
junction (GEJ) than gastric cancers, and in the intestinal 
subtype than diffuse types (43). Although there is a lower 
percentage of GEJ carcinoma and a higher percentage of 
diffuse-type histology in Asia (6), interestingly the average 
HER2-positivity rate for European countries is similar to 
that observed in Asian countries (44). To date, trastuzumab 
is the first and only targeted agent in gastric cancer 
approved by both the United States (45) and European 
authorities (46). It is indicated in combination with 
cisplatin and capecitabine or 5-fluorouracil in the first line 
treatment of HER2-overexpressing advanced GC; strong 
HER2 expression with IHC3+ or IHC2+ plus FISH+ is 
required by the European and Chinese guidelines.
The development of other targeted agents in advanced 
GC has however made slower progress. The addition of 
bevacizumab to chemotherapy did not result in significant 
OS benefit in the phase III AVAGAST trial (5); more 
recently the results of the REAL-3 study in abstract form 
reported an inferior OS with the addition of panitumumab 
to chemotherapy (47). Data on other agents are still 
awaited. Currently, prospective biomarker-driven clinical 
trials dedicated to specific patient populations enriched 
with rational molecular targets are lacking. The population-
based difference in the epidemiology and possibly biology of 
GC calls for international collaboration in future biomarker 
and clinical studies.
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Alternative therapy
The Chinese Guidelines included traditional Chinese 
medicine (TCM) to be considered as part of supportive 
care for GC. TCM is a holistic system of medicine 
including herbal medicine, acupuncture and moxibustion, 
tuina, dietary therapy, and qigong (48). There has been 
a long history of using TCM in treating various diseases 
including cancer in China. It is believed that TCM may 
lead to potential benefits such as reducing side effects 
of chemotherapy and radiotherapy, improving patients’ 
immune function, and enhancing the effects of conventional 
cancer treatments (49). 
Despite the plethora of case reports and series on TCM 
in cancer care (48,50), large-scale well-designed clinical 
trials are lacking. Nevertheless, a recent report on 399 
advanced GC patients with or without TCM treatment (51) 
represents the increasing effort to study TCM scientifically. 
Moreover, the Chinese government has approved the use of 
some Chinese herbal remedies in cancer treatment (49). It 
is therefore likely that TCM will continue to play a unique 
role in China.
Conclusions
The Chinese Guidelines addresses the need for population-
specific recommendations on the management of GC. 
They help to arouse awareness of GC among the Chinese 
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